Aims Myocardial fatty acid (FA) oxidation is regulated acutely by the FA supply and chronically at the transcriptional level owing to FA activation of peroxisome proliferator-activated receptor-a (PPARa). However, in vivo administration of PPARa ligands has not been shown to increase cardiac FA oxidation. In this study we have examined the cardiac response to in vivo administration of tetradecylthioacetic acid (TTA, 0.5% w/w added to the diet for 8 days), a PPAR agonist with primarily PPARa activity. Methods and results Despite the fact that TTA treatment decreased plasma concentrations of lipids [FA and triacylglycerols (TG)], hearts from TTA-treated mice showed increased mRNA expression of PPARa target genes. Cardiac substrate utilization, ventricular function, cardiac efficiency, and susceptibility to ischaemia-reperfusion were examined in isolated perfused hearts. In accordance with the mRNA changes, myocardial FA oxidation was increased 2.5-fold with a concomitant reduction in glucose oxidation. This increase in FA oxidation was abolished in PPARa-null mice. Thus, it appears that the metabolic effects of TTA on the heart must be owing to a direct stimulatory effect on cardiac PPARa. Hearts from TTA-treated mice also showed a marked reduction in cardiac efficiency (because of a two-fold increase in unloaded myocardial oxygen consumption) and decreased recovery of ventricular contractile function following low-flow ischaemia. Conclusion This study for the first time observed that in vivo administration of a synthetic PPARa ligand elevated FA oxidation, an effect that was also associated with decreased cardiac efficiency and reduced post-ischaemic functional recovery.
Introduction
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors regulating transcription of genes encoding proteins that affect lipid metabolism in several tissues, including the heart. 1 Of the PPAR isoforms (a, b/d, and g), PPARa is highly expressed in the heart and is thought to play an important role in the transcriptional regulation of cardiac metabolism under both physiological and pathophysiological conditions. 2, 3 Fatty acids (FA) are endogenous activators of PPARs and accordingly, FA activation of PPARa in isolated cardiomyocytes upregulates expression of key proteins that regulate nearly every step in the cellular FA utilization pathway, including sarcolemmal FA transport (cellular uptake), FA esterification to triacylglycerol (TG), mitochondrial transport, and b-oxidation. 4, 5 Genetically engineered mouse models with altered PPARa activity have provided further insight regarding the role of these nuclear receptors. PPARa-null mice exhibited diminished rates of cardiac FA oxidation 6, 7 and reduced expression of several genes involved in FA oxidation, 8 whereas cardiacspecific PPARa over-expressing (MHC-PPARa) mice showed increased FA oxidation and upregulation of genes involved in FA uptake. 7, 9 The contrasting metabolic phenotypes of these two genetically engineered mouse models support the notion that PPARa plays an important role in regulating cardiac energy metabolism.
Although studies employing isolated cardiomyocytes have shown that PPARa activation leads to upregulation of key † Both the authors have made equal contributions to this paper. enzymes in the FA-metabolizing pathway, 4 ,5 experiments using in vivo administration of PPARa ligands are inconsistent. Some reports show upregulation [10] [11] [12] while others report minor changes in PPARa target genes in the heart when compared with much more pronounced increases in liver. [12] [13] [14] The effect of in vivo PPARa agonist administration on cardiac substrate metabolism has not been well studied. In our own laboratory, we found that in vivo treatment with the PPARa ligand K-111 (previously called BM 17.0744) did not alter FA oxidation in normal mice. 15 In hyperlipidaemic animals, this treatment actually reduced cardiac FA utilization, 15, 16 probably a secondary response to reduced plasma FA supply to the heart.
Tetradecylthioacetic acid (TTA) is a non-b-oxidizable FA analogue. Although TTA is a pan PPAR agonist, 17, 18 it regulates lipid metabolism mainly through activation of PPARa. 18 TTA has been shown to increase peroxisomal proliferation and FA oxidation in the liver, 17 lower the concentration of plasma lipids, improve insulin sensitivity, and prevent feeding-induced obesity. 18 In this study, oral administration of TTA to mice markedly increased cardiac expression of PPARa target genes and increased FA oxidation, in spite of decreased circulating lipids. In accordance with other studies where myocardial FA oxidation was increased, 19, 20 these TTA-induced metabolic changes were associated with reduced cardiac efficiency and decreased tolerance to ischaemia.
Methods

Animals
Twelve-week-old male BALB/cA Bom mice were purchased from M&B Taconic (Ry, Denmark). In addition, male SVEV129 wild-type (WT) and PPARa-null mice (TG) were received as a gift from Dr Frank J. Gonzalez (National Cancer Institute, Bethesda, MD, USA). The latter groups were bred and housed in the animal facilities at the University of Oxford, UK, and the perfusion of the hearts of these mice were performed in UK. The rest of the work was carried out in Norway. All mice were housed in rooms maintained at 218C and 55% humidity with a 12-h light/dark cycle with free access to food and water. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the Norwegian National Animal Research Committee or the University of Oxford Animal Ethics Review Committees and the Home Office (London, UK). The treated mice received food mixed with 0.5% (w/w) TTA for a period of 8 days. Age-matched untreated SVEV129 mice served as controls for the PPARa KO mice. BALB/cA Bom mice were used for all other experiments.
Plasma parameters
Plasma glucose, non-esterified FA, and TG were determined in blood samples taken from the chest cavity of the animals (non-fasted) at the day of sacrifice, using commercial kits from Boehringer Mannheim (Mannheim, Germany), Wako Chemicals (Neuss, Germany), and ABX Diagnostics (Montpellier, France), respectively.
Real-time quantitative RT-PCR
Fresh samples from unperfused liver and heart (left ventricle) were immersed in RNAlater (Qiagen, Hilden, Germany) and stored at 48C until RNA extraction. Total RNA was extracted according to the RNeasy Fibrous Tissue Protocol kit (Qiagen Nordic-Norway). RNA concentration was measured spectrophotometrically (NanoDrop, Witec, Switzerland), and stored at 2808C before use. cDNAs were obtained from 1 mg total RNA according to iScript cDNA Synthesis Kit (BioRad, Sundbyberg, Sweden). Real-time PCR (qPCR) was performed in an ABI PRISM 7900 HT Fast real-time thermal cycler using a 1:4 dilution of the cDNA and the TaqMan Fast Universal PCR master mix (Applied Biosystems, Foster City, CA, USA). The primer/probe sequences for the genes studied (see Supplementary material online) were obtained from Eurogentec Ltd (Seraing, Belgium) or Roche Diagnostics GmbH (Roche Universal ProbeLibrary, Mannheim, Germany). Primers and TaqMan probes (2 mL of cDNA) were used in a 20 mL final volume. A negative control without cDNA template was included in every assay. The PCR efficiency for all genes was determined by performing a dilution series of a pool of all samples. House-keeping genes were selected on the basis of the average expression stability values determined with geNorm Normalisation kit 21 out of a selected pool of five to six candidate genes. The expression of target gene mRNAs was normalized to the geometric mean of the three best house-keeping genes. For quantification of cardiac mRNA content, we used the geometric mean of cyclo (cyclophilin), gapdh (glyceraldehyde-3-phosphate dehydrogenase), and hprt (hypoxanthine-guanine phosphoribosyl transferase); the mean of cyclo, gapdh, and sdha (succinate dehydrogenase complex subunit A) was used for quantifying hepatic mRNA content.
Heart perfusion
Mice were given an intraperitoneal injection of heparin (100 U) and anaesthetized with sodium pentobarbital (10 mg, i.p.). The heart was quickly excised and the aorta cannulated for perfusion in working mode; the left atrium was connected to a preload reservoir (12.5 mmHg), while the left ventricle was ejecting against an afterload column with a height corresponding to a pressure of 55 mmHg. A modified KHB buffer supplemented with 0.7 mM palmitate (bound to 3% BSA) and 5 mM glucose was used as perfusion medium.
For measurements of cardiac metabolism and susceptibility to ischaemia-reperfusion, the hearts were allowed to beat spontaneously, and peak systolic pressure (PSP) was recorded in the aortic line with a Codman Micro Sensor. Coronary flow (CF) was measured by timed collections of the effluent dripping from the heart, while aortic flow (AF) was determined by a drop counter at the outlet of the afterload line. After 30 min of perfusion, baseline (preischaemic) functional parameters were recorded, and thereafter hearts were subjected to 40 min low-flow ischaemia (1.68 mL/g dry weight/min) followed by 35 min reperfusion (5 min in Langendorff and 30 min in working mode). Postischaemic recovery of ventricular function was calculated based on values obtained at the end of reperfusion relative to pre-ischaemic baseline values. Glucose and palmitate oxidation were determined in the pre-ischaemic perfusion period by collection of 14 In a separate series of hearts, cardiac performance was measured using a 1.4 F micromanometer-conductance catheter (Millar Instruments, Houston, TX, USA) inserted into the left ventricle through the apex. Partial oxygen pressure in the buffer entering (PO 2-buffer ) and leaving (PO 2-effluent ) the heart was measured using fibre-optic oxygen probes (FOXY-AL300, Ocean Optics Ltd., Duiven, The Netherlands) placed in the preload line and in the pulmonary trunk, respectively. Myocardial oxygen consumption (MVO 2 ) was calculated by the following equation: MVO 2 ¼ [PO 2-buffer 2 PO 2-effluent ] Â Bunsen solubility coefficient of O 2 Â coronary flow. Electrodes were connected to the right atrium for electrical pacing of the heart. In order to determine cardiac efficiency, hearts were exposed to different workloads by changing preload (from 5 to 10 mmHg) and afterload (from 35 to 50 mmHg). Steady-state values of pressure-volume area (PVA) and MVO 2 were calculated at each workload. Analysis of the relationship between PVA and MVO 2 allowed determination of unloaded MVO 2 (y-intercept of the PVA-MVO 2 relationship), as well as contractile efficiency (the inverse slope of the PVA-MVO 2 relationship). Steady-state functional parameters were analysed at preand afterload settings of 10 and 50 mmHg, respectively. In addition, the slope of the regression line of the end-systolic pressure-volume relationship and the end-diastolic pressure-volume relationship, as well as the preload-recruitable stroke work index were assessed from a family of pressure-volume loops created by a temporary reduction of the preload.
Statistical analysis
Data are expressed as mean + SEM; mRNA data are normalized to untreated controls. Differences between groups with respect to cardiac mRNA, myocardial substrate oxidation, and cardiac efficiency were analysed using an unpaired t-test. Differences in substrate oxidation between hearts from TTA-treated and non-treated WT and PPARa-null mice were analysed by two-way analysis of variance (ANOVA), followed by Holm-Sidak's test. Finally, differences in postischaemic functional recovery were analysed using repeated measures ANOVA followed by an unpaired t-test. The overall significance level was 0.05.
Results
Biometric data
Eight days treatment with TTA reduced body weight by 8% as shown in Table 1 ; by comparison, untreated control mice exhibited a 4% increase in body weight. The TTA-induced decrease in body weight was associated with an approximately 20% lower food intake compared with untreated mice. TTA treatment also resulted in a significant reduction in plasma lipid and glucose levels. Heart weight and liver weight of TTA-treated mice were the same as in controls ( Table 1) .
Transcriptional changes in liver and heart
In agreement with the previous studies, 17 TTA treatment resulted in upregulation of PPARa target genes in the liver, including l-cpt1 (1.9 + 0.4-fold, P ¼ 0.013), pdk4 (4.2 + 1.2-fold, P ¼ 0.006), and ucp2 (2.2 + 0.4-fold, P ¼ 0.008). Analysis of myocardial mRNA levels also showed a significant upregulation of PPARa-target genes in hearts from TTAtreated mice, including m-cpt1, pdk4, ucp3, mte1, cte1, and mcd (Figure 1 ).
Myocardial metabolism
Isolated perfused hearts from TTA-treated BALB/c mice showed a 2.5-fold increase in FA oxidation ( Figure 2A ) with a concomitant decrease (247%) in glucose oxidation ( Figure 2B ). Despite the decrease in body weight in the TTAtreated mice, there was no increase in the plasma concentration of FA, indicating that the TTA-induced increase in FA oxidation was independent of the weight reduction. To find out whether the cardiometabolic effect of TTA was because of PPARa activation, FA and glucose oxidation were measured in hearts from TTA-treated WT and PPARanull mice. PPARa KO mice are on a SVEV129 background and, accordingly, both TTA-treated and untreated PPARa KO (TG) and normal SVEV129 (WT) mice were used in these experiments. In line with earlier studies, 6, 7 PPARa-null mice exhibited diminished rates of cardiac FA oxidation compared with WT mice ( Figure 2C) . Hearts from TTA--treated WT mice showed markedly increased values of FA oxidation combined with reduced glucose oxidation, whereas TTA had no effect on cardiac metabolism in hearts from PPARa-null mice ( Figure 2C and D) . Figure 1 Cardiac mRNA content of muscle type carnitine palmitoyl transferase1 (mcpt1), pyruvate dehydrogenase kinase 4 (pdk4), uncoupling protein 3 and 2 (ucp3, ucp2), mitochondrial and cytosolic thioesterase1 (mte1, cte1), and malonyl-CoA decarboxylase (mcd) in untreated (black bars) and TTA-treated (white bars) mice. Results are normalized to untreated controls and expressed as mean of eight hearts in each group. The geometric mean of cyclo, gapdh, and hprt was used as house-keeping genes. *P , 0.05 vs. hearts from untreated mice.
Ventricular function and tolerance to ischaemia
Assessment of mechanical function by pressure-volume analysis (Table 2 ) revealed that TTA treatment did not alter heart rate, ventricular pressure, or cardiac output. We did find, however, that TTA treatment significantly increased dP/dt max , end-systolic elastance (E es , i.e. the slope of the regression line of the end-systolic pressurevolume relationship) and the preload-recruitable stroke work (PRSW), suggesting that TTA treatment increased myocardial contractility. The relaxation constant t, dP/dt min , and the slope of the end-diastolic pressure-volume relationship were, however, not changed. As increased FA oxidation has been associated with reduced myocardial tolerance to ischaemia-reperfusion, hearts were exposed to 40 min low-flow ischaemia followed by 35 min reperfusion. Again, we found no differences with respect to pre-ischaemic cardiac function (Figure 3) . TTA treatment, however, resulted in reduced functional recovery, as indicated by a significant decrease in post-ischaemic recovery of aortic flow, cardiac output, and rate-pressure product.
Cardiac efficiency
The decreased tolerance to ischaemia-reperfusion in hearts with elevated FA oxidation has been associated with, and may be caused by, decreased cardiac efficiency. 19 In accordance with this notion we found that TTA treatment significantly reduced cardiac efficiency (Figure 4) . This inefficiency was revealed by a 97% increase in unloaded MVO 2 (elevation of the y-intercept of the regression line of the PVA:MVO 2 relationship), while contractile efficiency (the inverse slope of the regression line) was not altered. Steady-state parameters were obtained at pre-and afterloads of 10 and 50 mmHg, respectively. LVEDP, left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic pressure. t is the isovolumic relaxation constant analysed using Glantz method. The slope of the end-systolic pressure-volume relationship (E es ) and the end-diastolic pressurevolume relationship (EDPVR), as well as the preload-recruitable stroke work (PRSW) were assessed from a family of pressure-volume loops created by a temporary reduction of the preload. Results are mean of five hearts in each group. *P , 0.05 vs. hearts from untreated mice.
Discussion
PPARs are ligand-activated nuclear receptors that play an important role in the transcriptional regulation of lipid utilization. In this study, we have demonstrated that in vivo treatment with the PPAR agonist TTA leads to upregulation of PPARa target genes and increased myocardial fatty acid (FA) oxidation, despite decreased circulating levels of lipids. The finding that TTA treatment had no effect in PPARa-null mice proves that TTA mediates its effect on cardiac metabolism via PPARa activation. These data support the current view of PPARa as an important regulator of cardiac metabolism as shown previously using gain-and loss-of-function approaches, i.e. MHC-PPARa mice and PPARa-null mice.
7-9,24 TTA is a saturated FA which is modified by insertion of a single sulphur atom at the third position in the carbon backbone. The presence of the sulphur atom makes TTAcoenzyme A resistant to b-oxidation. Although studies have revealed that TTA is a pan PPAR agonist and the degree of activation of the different PPARs depends on the cell type studied, the ranking order of activation is: PPARa . PPARd . PPARg. 17 It is well documented that TTA has a hypolipidaemic effect, which has been linked to hepatic PPARa activation resulting in decreased expression of genes involved in vascular lipid transport and increased expression of genes involved in intracellular FA metabolism. 17, 18, 25, 26 Myocardial FA oxidation rate is largely determined by lipid supply to the heart. Thus, an acute increase in the plasma FA level in intact animals, 27 or increased perfusate FA in isolated heart perfusions, 19 will accelerate myocardial FA oxidation and reduce glucose utilization (Randle cycle). It is also known that chronic elevation of plasma lipids will increase the reliance on FA as energy substrate in the heart, because of transcriptional changes in metabolic enzymes (PPARa target genes).
2,3 Therefore, increased myocardial FA oxidation in type 2 diabetes/obesity is because of increased FA supply, as well as an FA-induced activation of cardiac PPARa. The regulatory role of PPARa in the heart has also been demonstrated by increased FA oxidation in MHC-PPARa mice and decreased FA oxidation in PPARa-null mice. [7] [8] [9] 24 In accordance with this, studies on isolated cardiomyocytes have shown that PPARa agonists lead to upregulation of PPAR target genes, coincident with increased FA oxidation rates. 4, 5 However, studies using in vivo administration of PPARa ligands in normal animals are less clear; increased or unchanged expression of cardiac PPARa-regulated genes has been reported, and transcriptional changes in the heart were minor when compared with much more pronounced increases in the liver. 9, [12] [13] [14] In the current study, the PPAR ligand TTA produced a large increment in cardiac expression of PPARa target genes and a 2.5-fold increase in myocardial FA oxidation. This finding is in accordance with a previous report showing increased oxidation of palmitoyl CoA in cardiac tissue from rats treated with TTA. 28 The fact that treatment with TTA increased myocardial FA oxidation, despite its hypolipidaemic effect indicates that the effect on cardiac metabolism must be direct owing to changes in gene expression rather than an altered FA supply. Although TTA is a pan-PPAR agonist, there is no evidence for direct PPARg regulation of heart metabolism. TTA could activate PPARd with stimulatory effects on FA oxidation. Our observation that TTA had no stimulatory effect on FA oxidation in perfused hearts from PPARa-null mice, however, argues strongly that the metabolic effects of TTA on the heart are because of PPARa activation.
It must be acknowledged, however, that elevated rates of cardiac FA oxidation after TTA treatment were observed with ex vivo hearts perfused with the same FA (palmitate) concentration as was used with untreated control heart perfusions. The net in vivo effect of TTA administration will have to take into consideration the opposing effects of TTA: to directly upregulate PPARa target genes in the heart that can result in increased rates of FA oxidation measured ex vivo vs. the indirect FA-lowering effect. Therefore, in vivo experimentation with a tracer FA analogue will be required to establish the net effect of TTA on myocardial FA oxidation. Notwithstanding this caveat, it is still notable that TTA treatment was able to show evidence for cardiac PPARa activation, and that this TTA-induced increase in myocardial FA oxidation is, in fact, in contrast to studies from our own laboratory; administration of the PPARa ligand K-111 (previously called BM 17.0744) did not alter FA oxidation in normal mice, 15 whereas both K-111 16 and fenofibrate 13 reduced myocardial FA oxidation in hyperlipidaemic mice, an effect which was most likely secondary to the lipid-lowering effect of these PPARa ligands. Our working hypothesis prior to the present study, therefore, was that PPARa ligands primarily affect cardiac metabolism indirectly through changes in the lipid supply. As far as we know, this study is the first to report that a synthetic PPAR ligand, following in vivo administration on a normal animal, promotes a switch in myocardial substrate preference towards FA.
The discrepancy between the cardiac metabolic effects of TTA compared with K-111 15, 16 and fenofibrate 13 may be related to differences in tissue uptake of the synthetic ligands and/or affinity for cardiac PPARa. TTA is possibly incorporated into chylomicrons during intestinal absorption, taken up in the lymph, and subsequently transported to the heart via the blood, allowing efficient uptake of the compound following lipoprotein lipase-catalysed degradation of the chylomicrons. In support of this view, Asiedu et al. 29 reported higher concentrations of TTA in the heart than in the liver of TTA-treated rats.
Both in vivo and ex vivo studies have shown that increased myocardial FA oxidation is associated with increased myocardial oxygen consumption (MVO 2 ) and decreased cardiac efficiency, 19, 27, 30 similarly to what has also been reported in diabetic hearts. 19, 20 In accordance with this, TTA treatment reduced cardiac efficiency because of a significant increase in unloaded MVO 2 . As increased MVO 2 may have deleterious consequences, particularly under conditions of limited oxygen supply by narrowing the window of reversible damage; it most likely caused the decreased post-ischaemic function in hearts from TTA-treated mice.
Elevated unloaded MVO 2 (work-independent MVO 2 ) reflects increased oxygen cost for non-mechanical purposes such as basal metabolism and excitation-contraction (E-C) coupling. The mechanism explaining this elevation in unloaded MVO 2 is not fully understood, but it may involve (i) increased oxygen demand related to the change in fuel consumption from glucose to FA (reduced P:O ratio), 31 (ii) induction of futile cycles, including FA-TG cycling, 32 and/ or increased H þ transport owing to uncoupling of glucose oxidation from glycolysis, 33 and/or (iii) mitochondrial uncoupling. 34 UCP3 has been proposed to play an important role in permitting high rates of FA oxidation, 35 and to contribute to reducing the mitochondrial membrane potential, 36 which could lead to increased MVO 2 . The lack of functional studies, however, makes it difficult to assign a role for UCP3 in the TTA-induced increase in MVO 2 . Finally, oxygen consumption in the unloaded heart also includes oxygen cost for E-C coupling, and it is well known that inotropic agents will increase unloaded MVO 2 . 37 We found that TTA treatment induced a clear increase in myocardial contractility, as indicated by both an increase in the dp/dt max , PRSW, and end-systolic elastance. Although the mechanism and physiological implication of this require further studies, it is likely that altered cardiac Ca 2þ handling may at least partly account for the TTA-induced increase in MVO 2 .
In conclusion, the present study has shown that in vivo treatment with TTA, a pan-PPAR agonist, leads to a marked increase in myocardial FA oxidation and a decrease in glucose oxidation, a response which was mediated via myocardial PPARa activation. TTA treatment was also associated with decreased cardiac efficiency and reduced postischaemic functional recovery. The TTA-induced increase in FA oxidation occurred in the face of decreased circulating lipid levels, demonstrating that an exogenous ligand can override the impact of endogenous (circulating) FAs on PPARa-mediated control of cardiac metabolism. It illustrates the potential of PPAR ligands as regulators of myocardial metabolism via both direct and indirect routes, and that further studies are required to clarify the cardiometabolic effects of these compounds.
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